Trade FATE anytime, even after market hours
Regulated by
MAS
Trusted by
400,000+ users
Fate Therapeutics, Inc. (FATE) is trading at US$2.45, down 3.74% today as of Aug 28, 13:04 EDT. The company has a market capitalisation of US$279.18M. Over the past 52 weeks, FATE has traded between US$0.93 and US$3.23. On Syfe you can trade FATE with $0 commission and add it to your watchlist.
| Previous close | US$2.54 |
|---|---|
| Market cap | US$279.18M |
| 52-week range | US$0.93 – US$3.23 |
| Volume | 1.56M |
| Exchange | US |
Add to Watchlist
Set Price Alert
Fate Therapeutics, Inc.
Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.
Year: 2013
Sector Update: Healthcare Stocks Softer Late Afternoon
Jul 9, 7:49 PM · MT Newswires
Sector Update: Healthcare
Jul 9, 7:23 PM · MT Newswires
Update: Fate Therapeutics Shares Rise After FDA Clears Investigational New Drug Application for FT839
Jul 9, 6:47 PM · MT Newswires
Fate Therapeutics Gets US FDA Approval of Investigational New Drug Application for FT839 to Treat Autoimmune Diseases
Jul 9, 1:30 PM · MT Newswires
Fate Therapeutics, Inc. (FATE) stock is trading at US$2.45, -3.74% from the previous close of US$2.54.
The market cap for Fate Therapeutics, Inc. (FATE) stock is approximately US$279.18M.
The 52-week high for Fate Therapeutics, Inc. (FATE) stock is US$3.23.
The 52-week low for Fate Therapeutics, Inc. (FATE) stock is US$0.93.
Fate Therapeutics, Inc. (FATE) does not currently pay a dividend.
Stay on top of FATE
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
